Fosun Pharma USA Inc.的动态

We are Fosun Pharma USA—and we’re moving faster than ever to reshape the future of cancer care. We're working tirelessly for our patients by taking on the most challenging solid tumors: Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Gastric Cancer. With 3 ground-breaking treatments in development working towards?US approval: -??Serplulimab Our innovative anti-PD-1 monoclonal antibody therapy, Serplulimab, reached significant clinical milestones. We successfully accelerated the ASTRIDE trial (NCT05468489) in the U.S. - ?Foritinib (SAF-189s) A Promising Innovation in Lung Cancer Treatment, SAF-189, a highly potent and brain-penetrating next-generation ALK/ROS1 inhibitor candidate, demonstrated compelling results in clinical trials. - HLX22 Fosun Pharma’s novel HER2-targeting antibody, HLX22, entered a Global Phase 3 clinical trial. We expect the first U.S. sites to be opened in early 2025. We’re addressing unmet needs—showing that rapid growth and innovation go hand in hand, with no patient left behind. With respective opportunities associated and held by our affiliates—134 preclinical treatments and 76 clinical-stage innovations,?we're proving that providing innovation for good health is more than a mission—it’s a passion that drives us to grow faster and?reach farther to serve patients who need us the most. Join us! Together, we can change the future of cancer care. #InnovativeMedicines #FosunPharmaUSA #HealthcareInnovation #OncologyLeadership #ES-SCLC? Meet us at the JP Morgan Healthcare Conference #JPM2025 To schedule a meeting, click this link: https://lnkd.in/gK-qhv-s

?Lung Cancer Awareness Month 2024 Each year, November is dedicated to increasing awareness about lung cancer, its risk factors, early detection, and treatment options. November is also a time to provide support to those affected by lung cancer. Lung cancer is the most common cancer type and the most common cause of cancer death in the world. In 2022 almost 2.5 million people were diagnosed with lung cancer and more than 1.8 million people died from the disease. Lung Cancer Awareness Month is an educational platform aiming to inform the public about the importance of smoking cessation, and advancements in lung cancer research and treatment. Although science has made incredible progress in developing diagnostics and innovative therapies, a lung cancer diagnosis still has a bad prognosis. ? At JJP Biologics, we're driven by a mission: to bring hope and new options to cancer patients who need it most. We're developing breakthrough treatments for those who are unresponsive to standard therapies, delivering truly personalized medicine through companion diagnostics. Because every patient deserves a tailored approach to care and a perspective of a healthy life. ? During this month on each Wednesday JJP Biologics ask attention for a scientific paper that eventually may contribute to development of novel therapeutic approaches. In the current paper, the authors demonstrate that BTLA can be constitutively detected in tumor cells by 40.2% of patients of NSCLC (I–III stage) using immunohistochemistry. This study is the first to analyze the correlations of BTLA with PD-1, PD-L1, and TILs. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose????? https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1008, #SMARTGOOSE, #LungCancerAwareness #PrecisionMedicine #JJPBiologics #InnovatingForHope

The Rapidly Emerging Platform of Bispecific Antibodies (BsAbs) ?? Bispecific antibodies (BsAbs) are revolutionizing cancer treatment by targeting two different antigens or epitopes simultaneously. The rise of innovative companies in this space is paving the way for groundbreaking advancements. ?? The landscape of BsAbs is expanding rapidly, with a growing list of clinical and preclinical antibodies showing promising efficacy as mono therapy. These antibodies are set to play a key role in engaging the immune system against tumor cells, akin to CAR-T programs ?? The future looks bright for NextGen BsAbs, expected to be more potent with longer half-lives, positioning them to compete effectively with CAR-T therapies. With over 100 assets in clinical development, more than 60 BsAb formats, and projected 2028 sales exceeding $10 billion, the potential for BsAbs in cancer treatment is immense ?? Bispecific antibodies represent a highly attractive class of antibodies with significant potential in cancer therapeutics. Stay tuned for the exciting developments in this space! #perspctives #eosintelligence #oncology #cancer #cancertreatment --------------------------------------------------------------------------------- Write to me at bhabesh.panigrahi@eos-intelligence to schedule a no-obligation consultation for a winning precision oncology treatment strategy

?? BREAKING NEWS IN LUNG CANCER TREATMENT ?? Regeneron Pharmaceuticals has shared positive five-year results from the phase 3 EMPOWER-Lung 1 trial of Libtayo (cemiplimab) for advanced non-small cell lung cancer (NSCLC). This study demonstrates groundbreaking results for those with PD-L1 expression of at least 50%! ? Key Findings: Median overall survival: ?? 26 months with Libtayo vs. 13 months with chemotherapy Progression-free survival: ? 8 months with Libtayo vs. 5 months with chemotherapy Objective response rate: ?? 46.5% with Libtayo vs. 21% with chemotherapy The trial revealed clinically meaningful benefits over a five-year follow-up with no new safety signals, making Libtayo a potential game-changer in treating advanced NSCLC. ??? Anna Baramidze, Head of Clinical Research at Todua Clinic , said: "The five-year results showcase the durable survival benefit and impressive efficacy of Libtayo compared to chemotherapy, especially in patients with high PD-L1 expression." ?? With lung cancer being the leading cause of cancer-related deaths globally, and NSCLC accounting for up to 85% of all diagnoses, this is a major milestone for advancing lung cancer care. ?? Could this be the future of first-line treatment for advanced NSCLC? #LungCancer #Oncology #CancerResearch #Libtayo #Regeneron #NSCLC #HealthcareInnovation #Pharmaceuticals #CancerCare #MedicalBreakthrough #linkedin

FDA just granted accelerated approval for tarlatamab-dlle for extensive-stage small-cell lung cancer (SCLC). In the early-stage SCLC trial performed by Imdelltra and Amgen,?tumors shrank in 40% of people?given 10 mg of tarlatamab every 2 weeks.? Despite being a fantastic result in SCLC, a 40% response rate indicates that a companion biomarker for this drug is an unmet need. At ESMO 2023, the team reported that they looked at DLL3 on tumor cells as a potential biomarker, but whether a person responded to the drug did not appear so far to be linked to having DLL3 in their tumors. At AACR in 2022 MD Anderson Cancer Center showed a poster on the expression of DLL3 in high-grade lung neuroendocrine tumors, showing that 94% of SCLC tumors expressed DLL3 to some degree. There are so many ways to analyze IHC. H-score is a great place to start but there are other ways to slice and dice the data. Not to mention that there are two components for bi-specifics that need to be considered. I'm excited to see the tarlatamab presentations at #ASCO2024 on the SCLC trial analyzed by the presence of brain metastasis and a second one in neuroendocrine prostate cancer! #ASCO24 #biomarkers #drugdevelopment #FDAapproval??#lungcancer #cancerimmunotherapy?#oncology -------- I'm Josie. I'm a consultant that builds biomarker strategies for biopharma. I have an extensive background in seeking predictive biomarkers for drug development. If you have an IHC biomarker that doesn't show the expected results, drop me a DM!

Open Exploration | Exploration of Targeted Anti-tumor Therapy ? It's time to Explore the mysteries of #TumorTherapy with us! ?? Tips! Welcome to your submission (Indexed in #PubMed #Scopus and #GoogleScholar with no #APCs) ?? New online #Review sharing! Happy reading! ?? Addressing the unmet need in #NSCLC progression with advances in second-line therapeutics ?? Authors: Robert Hsu* et al. ?? This review evaluates current and emerging second-line therapeutic options for advanced or metastatic NSCLC, focusing on their efficacy and potential to improve patient outcomes. ??♂? Welcome to read, forward, and share the article! https://lnkd.in/gxpfcik8 ?? This article belongs to the special issue?Immunotherapy Strategies for Non-small Cell Lung Cancer ? Non-small cell lung cancer (#NSCLC), antibody-drug conjugates (#ADCs), #SecondLineTherapy, #immunotherapy, #CancerProgression

Dive into the cutting-edge research on #TumorTherapy ?? with our latest article! ?? No #APCs, indexed in #PubMed, #Scopus, and #GoogleScholar. ?? Check out the insights on #NSCLC and #SecondLineTherapy by Robert Hsu et al. ???? Read, share, and stay ahead in the field! ?? #Immunotherapy #CancerProgression #ADCs

June is Cancer Immunotherapy Month. The Partnership for Accelerating Cancer Therapies (PACT), one of the flagship public-private partnerships managed by FNIH, aims to maximize the benefits of immunotherapies for all cancer patients. Part of the Cancer Moonshot Research Initiatives,?PACT?is studying?samples from 37 clinical trials representing 4,000 participants and 15+ types of cancer, to better understand when patients do or don’t respond to immunotherapy. We are proud to share this teaser video for a full video premiering next week, which will examine the partnership’s impact in the field of immunotherapy. The video will also highlight the crucial collaborations between The National Institutes of Health, FDA, academia, and the private sector, including the integral Cancer Immune Monitoring and Analysis Centers and the Cancer Immunologic Data Center (CIMAC-CIDC) Network. Learn more about?PACT: https://lnkd.in/eUh-Fdn3 #CancerImmunotherapyMonth #PACT #CancerMoonshot #Immunotherapy #CancerResearch #cancer National Cancer Institute (NCI) | AbbVie | Amgen | Boehringer Ingelheim | Bristol Myers Squibb | FDA| Genentech | Gilead Sciences | GSK | The Janssen Pharmaceutical Companies of Johnson & Johnson | Novartis | Pfizer | Sanofi | Dana-Farber Cancer Institute | MD Anderson Cancer Center Stanford University | ADENOID CYSTIC CARCINOMA RESEARCHFOUNDATION | Icahn School of Medicine at Mount Sinai

New Hope for Lung Cancer Patients: Tagrisso Approved for Stage III EGFR-Mutated NSCLC In a significant advancement for lung cancer treatment, the FDA has approved AstraZeneca's Tagrisso (osimertinib) for adult patients battling unresectable, Stage III EGFR-mutated non-small cell lung cancer (NSCLC). This decision follows a Priority Review based on promising data from the LAURA Phase III trial, showcasing the drug’s efficacy in patients whose disease has not progressed after undergoing platinum-based chemoradiation therapy. Key Highlights from the LAURA Trial ? Remarkable Efficacy: Tagrisso showed an 84% reduction in the risk of disease progression or death compared to placebo, translating to a median progression-free survival (PFS) of 39.1 months versus just 5.6 months for those on placebo. ? Wide Impact: This approval is pivotal as 15% of NSCLC patients in the U.S. have EGFR mutations, and nearly 20% of these have unresectable tumors, representing a significant unmet need in targeted therapy. The Journey Ahead Tagrisso, a third-generation EGFR tyrosine kinase inhibitor, has already been a game-changer in various stages of EGFRm NSCLC, and its approval for Stage III adds to its growing profile. The drug’s safety and tolerability align with its established reputation, with no new safety concerns reported during the trial. AstraZeneca’s commitment to advancing lung cancer treatment doesn’t stop here. Tagrisso is under evaluation for further indications globally, and the company is actively researching ways to combat resistance mechanisms to enhance patient outcomes. ?? GlobalData Healthcare analysis from Patent Analytics tool shows the key players with publications related to “Treating Non-Small Cell Lung Cancer (NSCLC)”. ? Connect with us today to explore the endless possibilities and propel your business forward! #lifesciences #pharmaceuticals #biotechnology #oncology #cancer

The future of antibody-drug conjugates (ADCs) in cancer treatment!? ? ADCs represent a cutting-edge approach in targeted cancer therapy, combining the specificity of monoclonal antibodies with potent cytotoxic agents. This innovative technology allows for precise delivery of cancer-fighting drugs directly to tumor cells, potentially improving efficacy while reducing side effects.? ? Key advantages of ADCs:? Targeted delivery to cancer cells? Reduced systemic toxicity? Potential for improved therapeutic outcomes? ? With 13 FDA-approved ADCs as of November 2023, including 6 for solid tumors, this field is rapidly advancing. ADCs have shown impressive results in clinical trials for various cancer types, including breast, ovarian, urothelial, and lung cancers.? ? By focusing on enhancing antibody stability, increasing drug-antibody ratios, and reducing immunogenicity, BIB continues to work towards developing novel ADC solutions with clients. As ADCs continue to demonstrate efficacy in various tumor types, we're committed to refining this technology and setting new benchmarks in therapeutic delivery systems.? ? For more information visit this link: https://lnkd.in/dtiyG_YV? ? #CancerResearch #Biotechnology #ADCs #TargetedTherapy #Innovation?#Biospace